Male-enhanced antigen 1 (MEA1)

Male-enhanced antigen 1 (MEA1) is a protein expressed primarily in testicular tissue, particularly involved in late spermatogenesis and potentially essential for normal testis development[1][5][9][3]. It is not currently regarded as a therapeutic target, and there are no drugs known to modulate its function, nor is it used as a diagnostic or predictive biomarker in clinical practice. MEA1 mutations or disruptions are associated with rare syndromes such as Hogue-Janssens syndrome 1, which highlights its importance in normal reproductive development[1]. No substantial evidence links MEA1 to major therapeutic areas such as cancer, inflammation, neurodegeneration, or infection. Most available data and curation resources (e.g., GeneCards, UniProt, HGNC) consistently highlight its restricted function in male gonadal tissue with no identified role as a clinically relevant drug target[1][9][5][3]. If more detailed or structured clinical or molecular data were to emerge, updates to its classification may be required, but current consensus places MEA1 among genes specific to reproductive tissue development rather than well-established molecular target classes.

Other names

MEAMEA-1HYSMale-enhanced antigen (H-Y structural gene)